

1 **Title: CTGF is a Modifiable Mediator of Flow-dependent Atherosclerosis under**
2 **Peripheral Artery Disease Conditions**

3 **Running title: CTGF Modulates Flow-dependent Atherosclerosis**

4 Authors:

5 Feifei Li MD, PhD (1) and Sandeep Kumar PhD (2)*, Anastassia Pokutta-Paskaleva
6 PhD (1), Victor Omojola BS (2), Dong-won Kang MS (2), Chanwoo Kim PhD (3),
7 Julia Raykin PhD (1), Carson Hoffmann MD (1,4), Maiko Teichmann MS (1,4), Jing
8 Ma BS (5), Hiromi Yanigasawa PhD (6), Andrew Leask PhD (7), Lucas Timmins PhD
9 (8), Xiangqin Cui PhD (9), Roy Sutliff PhD (10), Rudy L. Gleason, Jr. PhD (2,11),
10 Hanjoong Jo PhD (2), Luke Brewster MD, PhD (1,2,4)

11 **Key words:** Arterial stiffness; Peripheral artery disease; Disturbed flow;
12 Atherosclerosis; Fibulin 5; CCN2/CTGF

1) Department of Surgery, Emory University, Atlanta, GA, USA

2) Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of
Technology and Emory University, Atlanta, GA, USA.

3) Department of Advanced Animal Model Development, Non-Clinical Center, Osong
Medical Innovation Foundation (KBIO), Cheongju, Republic of Korea.

4) Research Services, Atlanta VA Medical Center, Decatur, GA, USA

5) Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of
Medicine, Emory University School of Medicine, Atlanta, GA

6) Life Science Center, Tsukuba Advanced Research Alliance, University of Tsukuba,

Tennodai 1-1-1, Tsukuba, Ibaraki 305-8577, Japan

7) College of Dentistry, University of Saskatchewan, 105 Wiggins Rd, Saskatoon, SK,

Canada

8) Department of Bioengineering, University of Utah, Salt Lake City, UT, USA

9) Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA,

USA

10) National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda,

MD, USA

11) George W. Woodruff School of Mechanical Engineering, Georgia Institute of

Technology, Atlanta, GA, USA

1 * FL and SK contributed equally for this work.

2

3

Corresponding author

Luke P. Brewster, MD, PhD

101 Woodruff Circle, WMB Suite 5105

Associate Professor of Surgery, Emory University; Division of Vascular Surgery

Section Chief, Vascular Surgery, Atlanta VA Medical Center; Surgical and Research

Services

lbrewst@emory.edu; luke.brewster@va.gov

1 **Abstract**

2 **Background**

3 Peripheral arterial disease (PAD) is the 3rd leading type of atherosclerotic disease
4 (ASD) morbidity. Arterial stiffness is intimately connected to the onset and
5 progression of peripheral artery disease (PAD). The role of arterial stiffening on
6 flow-mediated atherosclerotic plaque formation is not well understood. The objective
7 of this study is to discover endothelial cell (EC) pathways under PAD conditions and
8 test the modifiability of these pathways on ASD.

9 **Methods**

10 PAD conditions in mice were conferred by partial carotid ligation to induce disturbed
11 Flow (D-flow) in pre-stiffened Fibulin-5 knockout (KO) mice that lack normal elastin
12 function. EC pathways, including Connective tissue growth factor (CTGF/CCN) were
13 quantified by gene analysis and histology. Atherogenic mice had PCSK9 infection +
14 high fat diet. CTGF was inhibited in an EC-specific knockout (ECKO^{CTGF}) and with a
15 CTGF antibody (FG-3149). Human vascular tissue was used to validate PAD
16 biomechanics and CTGF upregulation.

17 **Results**

18 Biomechanical testing demonstrated that d-flow KO arteries mimic biomechanics of
19 PAD arteries. RNA microarray, qPCR, and immunohistochemistry identified EC
20 plasticity in these arteries compared to WT and KO under stable flow. Under
21 atherogenic conditions, KO arteries demonstrated vulnerable plaques not seen in
22 WT animals. CTGF expression was increased by d-flow, in KO arteries, in aged (18

1 months) WT arteries, and vascular tissue under d-flow. CTGF inhibition by ECKO^{CTGF}
2 favorably improved plaque characteristics in male but not female animals. FG-3149
3 treatment of ECWT^{CTGF} male animals delivered similar benefits to plaque
4 characteristics and arterial compliance.

5 **Conclusion**

6 ECs in PAD arteries exist under a complex hemodynamic environment that
7 integrates stiffness and d-flow into an atherogenic and inflammatory environment.
8 Stiffness + d-flow stimulates precocious onset of EC plasticity and a vulnerable
9 plaque phenotype. CTGF is a matricellular protein that can tune fibro-inflammatory
10 pathways. CTGF is a prominent mediator of D-flow-mediated arterial remodeling and
11 focal atherosclerotic plaque remodeling. Inhibition of CTGF improves plaque
12 phenotype and arterial compliance. CTGF-associated pathways hold promise as
13 therapeutic targets for PAD patients.

14 15 **Key words:**

16 Peripheral arterial disease; Flow-mediated atherosclerosis; Arterial stiffness;
17 endothelial cell plasticity; Connective tissue growth factor/CCN2; Fibulin 5

18 19 **Clinical Perspective:**

20
21 What is new?

- 22 • This study rigorously characterizes a biomechanical model of peripheral
23 arterial disease (PAD) for endothelial cells (ECs) and establishes the unique
24 molecular pathways for ECs under PAD (stiffness + disturbed flow) conditions.
- 25 • This study identifies that changes to EC plasticity occur rapidly under PAD
26 conditions and leads to vulnerable plaque profile under atherogenic
27 conditions.
- 28 • This study identifies CTGF upregulation in stiffness (in a knockout animal and
29 with aging), that this is increased by disturbed flow, and in both PAD arteries

- 1 and carotid endarterectomy samples exposed to disturbed flow.
- 2 • This study identifies that CTGF inhibition can favorably modulate
- 3 flow-mediated arterial stiffening and atherosclerotic plaque composition.
- 4

5 What are clinical implications?

- 6 • EC plasticity may play an important role in PAD progression and
- 7 atherosclerotic plaque formation
- 8 • Early interventions with CTGF targeted therapies may improve arterial health
- 9 and atherosclerotic plaque profiles in PAD
- 10
- 11
- 12
- 13

14 **Introduction**

15 Peripheral arterial disease (PAD) is a significant age-related medical condition that is

16 increasing in incidence and impacts 12-20% of the population over 65.¹ PAD is the 3rd

17 leading type of atherosclerotic disease (ASD) morbidity² and increases the risk of

18 cardiovascular events and mortality 2-3 fold.^{3,4} ASD is the most common feature of

19 PAD and current medications that target conventional ASD risk factors like

20 hypercholesterolemia, diabetes, hypertension have clear benefit for patients with

21 symptomatic PAD.⁵ However, targeting non-conventional ASD risk factors are the

22 next frontier in clinical management of patients.² As such, the discovery of druggable

23 targets of non-traditional pro-atherogenic pathways is an important endeavor.

24 Targeting inflammatory pathways may favorably prevent pathologic endothelial cell

25 (EC) plasticity. Both low and oscillatory wall shear stress, termed disturbed flow

26 (d-flow) and arterial stiffening independently promote EC fibrotic and inflammatory

27 pathways.^{6,7} Recent findings from our group revealed that d-flow patterns in regions

28 of atherosclerotic plaque dramatically alter ECs into proinflammatory, endothelial to

1 mesenchymal (EndMT) and immune cell (End-IT) transition phenotypes in a process
2 defined as endothelial reprogramming (EndRep) that contributes to ASD.⁸ Thus, PAD
3 biomechanics (stiff + d-flow) may stimulate EC inflammation in a synergistic manner
4 that promotes a pro-inflammatory vicious cycle, leading to the distinct differences in
5 atherosclerotic plaque characteristics in PAD compared to coronary artery
6 disease.⁹⁻¹³ Thus, mechanically-motivated PAD models may help discover and test
7 PAD-centric molecular pathways that are a currently unmet need.^{14,15}
8 Under healthy conditions, infra-inguinal arteries are naturally stiffer than elastic
9 arteries.¹⁶ Stiffened arterial biomechanics are pathognomonic for PAD, and arterial
10 stiffness contributes to both PAD and ASD more broadly.^{17,18} This stiffening appears
11 to be an important contributor to PAD and PAD symptoms.¹⁹ As such, baseline
12 stiffened arterial mechanics may influence the onset and progression of PAD in these
13 arteries.²⁰⁻²² The fibulin-5 (Fbln5) knockout mouse (KO) is an ideal murine model of
14 arterial stiffening.²³ This KO has a deficiency in elastin-based arterial wall
15 mechanics,²⁴⁻²⁶ and in non-diseased states, KO carotid arteries are circumferentially
16 and axially stiffer than arteries from wild-type (WT) mice.²⁷
17 We have found that d-flow induces stiffens otherwise healthy arteries through
18 flow-sensitive matricellular proteins that modulate fibrosis and fibro-inflammation,
19 including thrombospondin-1 (TSP-1).⁷ The fibro-inflammatory molecular pathways
20 particular to PAD biomechanics, and by which EC plasticity is induced in PAD, are
21 not well understood, but likely very important to the development of novel and
22 PAD-centric therapies. We hypothesize that it is the combination of arterial stiffening

1 and d-flow that promotes the most pernicious ASD, and that certain fibrotic and/or
2 fibro-inflammatory pathways mediate the pathologic EC plasticity induced under PAD
3 conditions. To test this hypothesis, the objectives of this study were to: 1) develop a
4 murine model of PAD mechanics (stiff + d-flow) and determine the impact of these
5 PAD mechanics on EC pathways and plasticity; 2) quantify differences in
6 flow-mediated atherosclerotic plaque in stiffened KO versus wild type (WT) arteries in
7 atherogenic mice; 3) identify prominent fibrotic mediator (CTGF/CCN2) in ECs from
8 KO and aged mice under d-flow conditions, and in vascular tissue exposed to d-flow
9 (PAD arteries and carotid endarterectomy samples); 4) investigate modifiability of
10 CTGF signaling on arterial stiffness and atherosclerotic plaque in an EC-specific
11 knockout (ECKO^{CTGF}) compared to WT control (ECWT^{CTGF}) male and female mice; 5)
12 Finally, to test the translational potential of a CTGF antibody (FG-3149) in WT
13 (ECWT^{CTGF}) mice.

14 **Methods**

15 **1) Animal Handling**

16 All mouse studies performed here were approved by the Institutional Animal Care
17 and Use Committee (IACUC) at Emory University and under the established
18 guidelines and regulations consistent with federal assurance. Fibulin-5 knockout (KO)
19 [C57Bl/6 x 129S2/SvPas] mice were generated from a heterozygous breeding pair
20 originally obtained from Dr. Hiromi Yanagisawa through MTA with
21 UT-Southwestern.²⁶ Wild-type littermates were used as control. Constitutive

1 endothelial cell (EC)-specific CTGF knockout (CTGF^{fl/fl}; Cdh5 Cre^{+/-}) mice were
2 generated by breeding CTGF^{fl/fl} mice (generously provided by Dr. Andrew Leask)
3 with transgenic Cdh5-cre^{7Mia} mice (Jackson Lab). The CTGF^{fl} allele was converted to
4 null allele by EC-specific Cdh5 Cre-mediated excision. ECWT^{CTGF} (CTGF^{fl/fl}; Cdh5
5 Cre^{-/-}) littermates were used as control group. The expression of Cre recombinase in
6 endothelial cells was validated by breeding the Cre mice with Ai14 reporter mice
7 (B6.Cg-Gt (ROSA)26Sortm14(CAG-tdTomato)Hze/J, Jackson Lab). ECKO^{CTGF}
8 (CTGF^{fl/fl}; Cdh5 Cre^{+/-}) mice showed no difference in an initial clinical and biological
9 analysis at baseline, including body weight and survival. Supplemental Figure 1
10 provides an overview of the animal experimental methodology and time points for
11 arterial remodeling studies.

12 **2) Partial Carotid Ligation Model of D-flow**

13 In the partial carotid ligation model (PCL), three of the four caudal branches of the left
14 carotid arteries (LCAs) were ligated as published,²⁸ resulting in a d-flow in LCAs.
15 Right carotid arteries (RCAs) were not manipulated and had stable flow (s-flow). PCL
16 was performed on all mice groups as listed in Supplemental Figure 1. The in vivo
17 hemodynamic environment in the carotid arteries was characterized at 2 and 4
18 weeks after PCL using ultrasonography. Blood pressure (BP) was assessed in all
19 murine groups using the CODA noninvasive BP system (a tail-cuff method, Kent
20 Scientific Corporation).

21 **3) Biomechanical Testing of Arterial Stiffness**

22 To compare the biomechanical properties, the carotid arteries were harvested from

1 mice quickly after CO₂ asphyxiation, perfused with saline, isolated, excised, and
2 frozen, prior to being mounted on an ex vivo bioreactor/biomechanical testing device
3 for cylindrical biaxial biomechanical testing as published.²⁷

4 **4) Endothelial Cell Function in vivo**

5 Age and sex-matched KO and WT carotid arteries were isometrically mounted on
6 wires, placed in an organ chamber containing Krebs-Henseleit buffer (pH is 7.4 when
7 bubbled with 95% O₂, 5% CO₂ at 37 °C) and connected to a Harvard apparatus
8 differential capacitor force transducer. For each carotid, tension was adjusted to 7.5
9 mN and then returned to a resting tension 5 mN that yielded maximal contractile
10 response to 50 mM potassium chloride. Data are recorded using PowerLab digital
11 acquisition and analyzed using Chart Software. Results are expressed as
12 mean±SEM. Following precontraction with 2-5 μM phenylephrine, a concentration
13 which yields 80-90% maximum contraction, relaxation responses were examined in
14 response to methacholine (1 nM to 100 M), and the NO donor, sodium nitroprusside
15 (SNP; 1 nM to 100 M). Relaxations were calculated as a percent of the
16 pre-constricted tone induced by phenylephrine. Statistical analyses were performed
17 by two-way ANOVA with Tukey's post-test repeated measures.

18 **5) EC-enriched RNA Isolation from Carotid Arteries**

19 Total RNA from intima (EC-enriched) was collected from KO and WT LCAs and
20 RCAs 24 hours post partial carotid ligation as published.⁷

21 **6) Microarray Procedure, Data Analysis, and Bioinformatics**

22 EC enriched RNA from 9 LCAs and 9 RCAs in KO animals were pooled for

1 microarray analysis (n=3 using total of 9 mice per group). RNA sample quality was
2 confirmed, and then samples were amplified and analyzed as a microarray using the
3 MouseWG-6 v2 expression BeadChip array by the Emory Winship Cancer Genomics
4 Core. The normalized microarray data was analyzed statistically, and the statistically
5 significant genes that were differentially expressed genes (LCA vs. RCA) were
6 screened for greater than 1.5 folds increase. The pathway enrichment analysis was
7 performed by mapping these differentially expressed genes to GeneGO's
8 MetaCore™. This program functions as an integrated software suite for functional
9 analysis of signaling pathways. GeneGO pathways were enriched by the 0.01 gene
10 list derived from the EC-enriched microarray data. The meta-data was uploaded to
11 the GEO Repository (GSE222583).

12 **7) En face staining for EC Plasticity**

13 Three days after LCA partial ligation, mice were euthanized by CO₂ inhalation and
14 perfused with saline containing heparin, followed by a second perfusion with 10%
15 formalin. LCA and RCA were carefully cleaned and dissected free of surrounding
16 tissues and fats. LCA and RCA were en face stained with VE-cadherin antibody (BD
17 Biosciences) and α-SMA antibody (abcam). LCA and RCA were counterstained
18 using DAPI (Sigma) and mounted on glass slides using fluorescence mounting
19 medium (Dako). En face images were collected with a Zeiss LSM 510 META
20 confocal microscope.

21 **8) Murine Model of Atherosclerosis**

22 Atherosclerosis in left carotid arteries was induced in all murine groups using male

1 and female mice aged 12-20 weeks old as published.²⁹

2 **9) Histological and Immunohistochemical Analysis**

3 Oil red O (ORO), H&E, Masson's trichrome staining, and elastin autofluorescence

4 were conducted on sections of common carotid arteries. Lipids were detected with

5 ORO (Sigma) staining following the standard protocol as described.²⁸ Masson's

6 trichrome staining was used for the assessment of collagen composition of the

7 atherosclerotic plaque. Elastin architecture was visualized by autofluorescence.

8 Immunohistochemical (IHC) staining of CD68 (BioRad) was applied to quantify

9 macrophage positive area. The quantitative assessments of the arterial wall and

10 necrotic area were blinded and quantified using Image J program. Each value was

11 based on 3 replicates. Unpaired, two-tailed t-test was used to compare mean values

12 of comparison d-flow carotid arteries with statistical significance at $P < 0.05$.

13 **10) Human Tissue Validation**

14 Human artery samples from PAD and carotid endarterectomy (CEA) patients

15 (Supplementary Tables 1 and 2) were collected from operative specimens after

16 informed consent under an IRB approved protocol (Emory University approved IRB

17 protocol numbers: 51432 and 70813). Arterial specimens were segregated prior to

18 testing into d-flow conditions if there was not inline flow to the artery as validated and

19 published prior⁷. In contrast, s-flow was defined in the same way as murine RCAs

20 and attributed to arteries with inline flow to them. All d-flow arteries were in patients

21 with proximal inflow occlusion and distal reconstitution through collateral pathways.

22 All s-flow arteries had inline flow without obstructive PAD.

1 **11) CTGF Inhibition on Murine Atherosclerosis Model**

2 The effects of CTGF inhibition on atherosclerosis development were examined
3 through EC-specific CTGF knockout and CTGF monoclonal antibody (FG-3149)
4 treatment in carotid atherosclerosis model. FG-3149 was generously donated to the
5 Brewster laboratory by FibroGen Inc. (San Francisco, CA). Male ECWT^{CTGF} mice
6 under atherosclerosis model were assigned to 2 antibody treatment groups: sham
7 antibody (IgG; n=6) and FG-3149 (n=6). Antibodies were administered by
8 intraperitoneal injection twice weekly at 30 mg/kg since day 1 after PCL for one
9 month.

10 **12) Statistics**

11 Where not already stated, unpaired t-test were performed with GraphPad Prism
12 (GraphPad Software). Parameters such as sample size, the number of replicates, the
13 number of independent experiments, measures of center, dispersion, and precision
14 (mean \pm SD), and statistical significance are reported in figures and figure legends.
15 Statistical significance was set at $P < 0.05$.

16 **Results**

17 **KO carotid arteries mechanics:**

18 To compare KO and WT carotid arteries to PAD arteries, we used the ϕ_E
19 (d-flow/s-flow ratio) of respective murine carotid artery elastic moduli and compared
20 this to that of PAD arteries/aged healthy artery elastic moduli. Here, we found that
21 KO arteries closely aligned with an approximately 3 fold stiffer ratio over physiologic
22 mean pressures that was similar to that characterized in PAD arteries (Figure 1A). To

1 identify the baseline stiffness of KO carotid arteries to that of aged control carotid
2 arteries, we compared the compliance curves of unmanipulated KO arteries to
3 80-week old (~18 months old) aged WT control mice arteries. Here we found that the
4 compliance of unmanipulated (stable or s-flow) KO arteries were overall similar to
5 aged WT arteries but even stiffer than aged control arteries from 60-80 mmHg
6 (Figure 1B). To compare the impact of d-flow on KO carotid artery stiffening, we
7 compared pressure-diameter and compliance curves of KO left carotid arteries
8 (LCAs) exposed to d-flow to unmanipulated right carotid arteries (RCAs), which have
9 stable flow (s-flow). After d-flow, KO LCAs underwent profound stiffening in the range
10 of physiologic mean pressures, which is outlined by the box (Figure 1C, D). There
11 were no differences in arterial stiffening in KO female versus male carotid arteries,
12 regardless of flow conditions (Supplementary Figure 2). KO arteries had lower in vivo
13 axial stretches (axial stiffening) with KO d-flow arteries the least compliant (Aged
14 WT>KO RCA>KO LCA; Figure 1E). However, both KO RCAs and LCAs have robust
15 residual stresses that are not further increased under d-flow (Figure 1F). PAD
16 arteries have EC dysfunction. To test EC dysfunction in KO and WT arteries,
17 EC-dependent and independent relaxation of KO and WT carotid arteries was
18 performed. KO (but not WT) carotid arteries exhibited a basal EC dysfunction,
19 indicated by impaired endothelial dependent vasodilation in arterial ring testing
20 (Figure 1G) that was ameliorated by exogenous sodium nitroprusside (Figure 1H).

21 **Validating d-flow environment/EC response to d-flow in KO carotid arteries:**
22 Next, the fidelity of the d-flow environment over the experimental time course was

1 verified using duplex ultrasound (2/4 weeks). The RCA demonstrates s-flow with
2 laminar WSS, whereas the LCA demonstrates low and oscillatory wall shear stress
3 (Figure 2A-C). To identify early EC-enriched RNA pathways in KO arteries, we
4 examined intimal RNA after 24 hours of d-flow. ECs on the d-flow, KO LCAs had
5 significant downward expression of PECAM-1 and similar α -SMA levels (Figure 2D).
6 By 72 hours of d-flow, en face staining of the intima demonstrates increased
7 expression of α -SMA in the KO LCAs compared to d-flow WT LCAs (Figure 2H, F),
8 as well as compared to both KO and WT RCAs, which were exposed to s-flow
9 (Figure 2G, E). This induction of EC plasticity towards EndMT in KO + d-flow was
10 verified in microarray pathway analysis and compared to that of d-flow, WT arteries
11 (Figure 2I, J). Here the top 5 identified differentially expressed clusters in KO carotid
12 arteries included cytoskeleton remodeling signaling pathways (including TGF and
13 Wnt) along with the EndMT pathways. Venn diagram of microarray data comparing
14 flow mediated differences within the KO and WT arteries identified only 24
15 overlapping genes, and 138 or 398 gene differences between the groups. This
16 identifies disparate genetic fingerprints between the KO and WT arteries under flow
17 (Supplementary Figure 3A, B; Supplementary Data File).

18 **KO carotid artery plaque under d-flow + atherogenic conditions:**

19 Since many of the identified fibro-inflammatory pathways that affect EC plasticity and
20 arterial stiffening may also contribute to ASD plaque remodeling, an atherogenic
21 environment was imposed on KO animals +/- d-flow; WT animals under the same
22 conditions served as normal arterial compliance control animals. Histologic

1 examination of carotid artery plaques was performed for weeks after induction of
2 d-flow. Only LCAs under d-flow developed plaques; this occurred in both WT and KO
3 animals. (Representative histology presented in Figure 3A-E) Here, pre-stiffened KO
4 arteries demonstrated a more aggressive, vulnerable atherosclerotic plaque
5 formation in response to d-flow. Specifically, KO LCAs had significantly more plaque
6 area, lipid deposition in the plaque, percent necrotic area in the plaque, and
7 macrophage content in the plaque (Figure 3F-I). KO arteries also had increased
8 inner and outer diameter (Figure 3L-M), consistent with Glagov's remodeling,³⁰ that
9 correlated with an increase in elastin breaks (Figure 3N). In contrast, WT LCAs
10 demonstrated a more fibrotic plaque phenotype with medial thickening and greater
11 collagen content (Figure 3J, O-P). Atherogenic conditions did unmask an increase
12 MAP in WT (compared to KO) male animals that did not exist under standard,
13 non-atherogenic conditions (Supplementary Figure 4C, 3rd panel). There were no
14 differences in the serum lipid levels between KO and WT animals (Supplementary
15 Figure 4E-L).

16 **CTGF expression in response to aging and d-flow:**

17 When examining our WT and KO carotid artery gene expression data under d-flow,
18 we found that CTGF was increased under d-flow and in KO compared to WT arteries.
19 Specifically, and in a stair-step manner, CTGF was upregulated in d-flow WT LCAs
20 compared to s-flow RCAs, and that s-flow KO RCAs had similar CTGF expression to
21 that of d-flow WT LCAs. Further, CTGF expression increases in d-flow KO LCA
22 compared to s-flow KO RCAs (Figure 4A). Since arterial stiffening and PAD is also

1 associated with aging, we queried our young versus aged (18 months) murine
2 s-flow/d-flow WT gene dataset to determine the impact of d-flow and aging on
3 CTGF.³¹ We discovered a similar stair-step relationship for d-flow and aging in the
4 upregulation of CTGF. Here, d-flow upregulates CTGF in young animal carotid
5 arteries compared to s-flow, and older s-flow arteries have similar CTGF expression
6 to that of younger d-flow arteries. Similarly, older d-flow carotid arteries had
7 significantly greater CTGF expression (Figure 4B) than older, s-flow arteries.
8 Prior to testing the modifiability of CTGF expression under PAD conditions, we
9 validated the importance of CTGF in human PAD pathology. IHC staining for CTGF
10 was quantified in d-flow PAD arteries and compared to aged infra-inguinal arteries
11 under s-flow (patient information in Supplementary Table 1). To further test the role
12 of d-flow on CTGF expression in vascular patients, we compared CTGF staining in
13 carotid endarterectomy samples (patient information in Supplementary Table 2).
14 Here too, we found CTGF significantly upregulated both in the intima and remainder
15 of the artery in PAD arteries and carotid endarterectomy samples compared to aged
16 s-flow arteries (Figure 4C-G), establishing CTGF is increased under d-flow in PAD
17 and carotid arteries.

18 **Targeted CTGF therapies manipulate flow-mediated atherosclerotic plaques:**

19 To test the role of EC CTGF in flow-mediated atherosclerotic plaque biology, we
20 created an EC-specific CTGF KO mice strain (ECKO^{CTGF}). We imposed atherogenic
21 conditions in the same manner as prior (PCSK9 infection + high fat diet), then
22 created d-flow by PCL. Male ECKO^{CTGF} mice developed less plaque burden and

1 percent macrophage content in plaque under d-flow + atherogenic conditions
2 compared to littermate control animals (Figure 5A, F, I). Female ECKO^{CTGF} mice
3 developed a trend (P=.06) towards decreased necrotic area compared to littermate
4 control animals (Supplemental Figure 5H) but were otherwise similar to control
5 animals. To test the effect of CTGF inhibition with a monoclonal antibody (FG-3149;
6 donated for research testing by Fibrogen, Inc.) as a translational therapeutic, male
7 littermate WT control animals (ECWT^{CTGF}) under atherogenic conditions were treated
8 with FG-3149 or control IgG antibody beginning on postoperative day 1 after PCL
9 (induction of d-flow). Again, CTGF inhibition impacted flow-mediated carotid plaque.
10 Specifically, plaque in d-flow LCA of animals treated with CTGF antibody (FG-3149)
11 developed less lipid deposition and percent necrotic area in their plaques compared
12 to IgG (Figure 6A, G-H).

13 **Targeted CTGF therapies improves arterial mechanics during flow-mediated**
14 **remodeling:**

15 To test whether the effect of EC-specific CTGF knockout on artery stiffness, biaxial
16 mechanical tests were applied to carotid arteries from ECWT^{CTGF} and ECKO^{CTGF}
17 after 6 weeks of PCL under non-atherogenic conditions. Differences between
18 LCA/RCA compliance curves are over a narrower pressure range in the ECKO^{CTGF}
19 compared to ECWT^{CTGF} (Figure 7A, B). Similarly, animals treated with CTGF
20 antibody (FG-3149) have similar differences, also over a narrower pressure range
21 compared to IgG control arteries (Figure 7E, F). The axial stiffening of the ECWT^{CTGF}
22 LCA compared to RCA trended towards significance (P=.05), whereas it did not

1 (compliance more preserved) in the ECKO^{CTGF} LCAs (Figure 7C). Axial stiffness was
2 significantly greater in IgG treated animals' LCA compared to RCA, but not FG-3149
3 treated arteries, which were protected (Figure 7G). Moreover, under atherogenic
4 conditions, the residual stresses of the ECKO^{CTGF} LCAs are significantly decreased
5 compared to ECWT^{CTGF} LCAs (Figure 7D), supporting a favorable local impact on
6 plaque mechanics.

7 **Discussion**

8 This study has 5 important findings. First, this work characterized a murine model
9 that mimics the biomechanics of PAD and establishes the powerful effect of
10 biomechanical forces acting on ECs under these PAD conditions (stiffness + d-flow in
11 an athero-inflammatory environment) on EC pathways and plasticity. As such, this
12 work contributes to the emerging collective work linking arterial stiffness and vascular
13 disease.^{32,33} The addition of d-flow to KO arteries builds on prior work characterizing
14 the stiffened profile of Fbln5 KO arteries previously that was mostly due to elastin
15 dysfunction,²⁷ and our prior discovery that d-flow mediated arterial stiffening was
16 from fibrotic pathway upregulation and collagen deposition⁷. Here, we quantify that
17 this combination mimics the mechanical environment of PAD arteries.

18 EC plasticity is a likely mechanism as we demonstrate rapid EndMT changes in the
19 endothelium of KO mice exposed to d-flow. A single cell RNA (scRNA) sequencing
20 analysis by the Jo lab characterized the effect of d-flow on individual EC plasticity.⁸
21 Here, d-flow alone, promoted EC plasticity into a wide variety of phenotypes from
22 inflammatory to mesenchymal (i.e., EndMT), immune cell-like, stem/progenitor-like,

1 and hematopoietic phenotypes over ~14 days. The impact of d-flow under stiffened
2 conditions appears to speed up this process in the murine model (3 days compared
3 to two weeks). This has clinical implications because PAD most commonly presents
4 as a progressive obstructive disease due to focal deposition of atherosclerotic plaque
5 at branch points, where the arteries exhibit d-flow patterns. Thus, conceptually in
6 PAD, this work supports the paradigm that ECs in already stiff PAD arteries and
7 exposed to d-flow, are “tuned” to direct a *unique molecular signature* to d-flow that is
8 more pernicious than that seen in less stiff arteries. This appears to be further tuned
9 by the matricellular protein, CTGF. Since ECs in the endothelium do not act as one,
10 but rather undergo EndRep into non-conventional ECs that can direct focal
11 inflammation and progression ASD. How EC plasticity and matricellular proteins
12 interact, and how can they be harnessed to develop next generation PAD therapies is
13 a promising avenue for future discovery.

14 Secondly, the combination of stiffness + d-flow leads to this particularly aggressive
15 atherosclerotic plaque remodeling as evidenced by plaque area, plaque content, and
16 elastin breaks. Interventions that limit stiffness (targeted CTGF therapies) or promote
17 s-flow over d-flow (revascularization procedures) may reverse the velocity of
18 atherosclerotic remodeling and maybe outcome of this process, but this remains to be
19 definitively proven. It is highly likely that the effect of PAD conditions (stiff + d-flow) on
20 EC plasticity will be an important surrogate for future therapeutic testing due to the
21 known causative role for EndMT in atherosclerotic plaque formation.³⁴ There are also
22 several studies supporting an important role for matrix stiffness on pathologic

1 behavior of other cell types that provides broader support of this concept. For
2 example, In myofibroblasts, matrix stiffness promotes the activation of RhoA,³⁵ which
3 is the upstream regulator of transcription factor Twist1,³⁶ Snail1 and Slug.³⁷ Also,
4 YAP/Taz is recognized as the key regulator in matrix stiffness induced EndMT
5 through collaboration with Snail1/Slug in mesenchymal stem cells.³⁸ Interestingly,
6 YAP/Taz is both upstream and downstream from CTGF,³⁹ making CTGF particularly
7 exciting as a therapeutic target. Similar early gene regulation is seen in our
8 EC-enriched gene analysis. (Supplementary Data File)
9 Thirdly, we identified CTGF as a prominent target as a fibrotic mediator of stiffened
10 arterial remodeling under d-flow conditions, and in both KO and aged animals. We
11 validated CTGF was upregulated in ECs from KO and aged mice under d-flow
12 conditions, and in vascular tissue exposed to d-flow (PAD arteries and carotid
13 endarterectomy samples). CTGF is a multifunctional matricellular protein that is
14 composed of 4 modules, i.e., IGFBP (insulin-like growth fac-tor binding protein)-like,
15 VWC (von Willebrand factor type C), TSP1 (thrombospondin 1 type 1) repeat, and
16 CT (C-terminal cystine knot) module. All 4 of these modules comprising CTGF are
17 highly interactive with a variety of other molecules such as growth factor binding,
18 integrin recognition, and interaction(s) with heparin and proteoglycans. CTGF has an
19 important role in cell adhesion, migration and proliferation, which is correlated to the
20 initiation and progression of atherosclerotic lesions in humans and in animal
21 models.⁴⁰ Although CTGF is highly expressed in complicated compared with fibrous
22 plaques,⁴¹ no clear mechanisms have been attributed to CTGF in atherosclerotic

1 plaque. Our work here supports this may be due in part to favorable modulation of
2 arterial compliance.

3 Fourth, in order to test the modifiability of CTGF signaling on arterial stiffness and
4 atherosclerotic plaque composition, we induced d-flow in an EC-specific knockout
5 (ECKO^{CTGF}) compared to WT control (ECWT^{CTGF}) male and female mice under
6 standard and atherogenic conditions. Here we identified a critical and modifiable role
7 for CTGF in both arterial stiffening and atherosclerotic plaque characteristics. To our
8 surprise, the favorable plaque findings appeared to be limited to male animals. Here,
9 we discovered that CTGF ECs specific knockout (ECKO^{CTGF}) have decreased
10 atherosclerotic plaque size in male mice compared with littermates. This was not
11 seen in female mice. Due to these findings, we limited our testing of CTGF mAb to
12 male littermate control mice (ECWT^{CTGF}) tested against IgG treated control animals.
13 Here we found FG-3149 decreased lipid content and necrotic area in plaques.
14 Sex-based differences in PAD is an important area of research, and it is possible that
15 matricellular proteins, like CTGF, could be differentially regulated in this manner. Sex
16 differences may impact the benefits of CTGF inhibition on atherosclerotic plaque
17 biology.

18 While the burden of PAD with increasing age is shared by both sexes,⁴² clinically, PAD
19 in women is delayed with age proportionately to the delayed onset of arterial stiffness
20 and EC dysfunction, ~10 years after men,⁴² delays in stiffening are also seen in
21 murine models.⁴³ Arterial stiffness is of particular interest to sex-based differences
22 because not only is it a risk factor for CV disease and mortality,⁴⁴ but the association

1 between arterial stiffness and mortality is ~2 fold greater in women.⁴⁵ In this
2 manuscript, we focused on the EC response to PAD mechanics, but further
3 sex-based investigation of matricellular pathways under PAD conditions is warranted.
4 Finally, we tested the translational potential of a CTGF antibody (FG-3149) in WT
5 (ECWT^{CTGF}) male mice. Here too, we found favorable modulation of atherosclerotic
6 plaque with our antibody therapy. There is likely an important interaction between
7 CTGF modulation of fibro-inflammatory pathways induced by d-flow. We know that
8 d-flow induces proinflammatory gene expression and induces atherosclerosis
9 development.⁴⁶ Here, we uniquely have identified that CTGF increases in d-flow, in
10 KO arteries, and in older arteries (that have similar mechanics to KO arteries under
11 s-flow), and validated that CTGF is increased under d-flow conditions in PAD arteries
12 and carotid endarterectomy plaques compared to aged control arteries. The
13 interaction of fibroinflammatory mediators, like CTGF, on atherosclerotic plaque is an
14 important avenue of current discovery. Matricellular proteins, like CTGF, can tune
15 molecular pathways into vicious cycles, and as such, hold promise as therapeutic
16 targets under hostile conditions. Since ECs sense both shear stress and arterial
17 stiffness, it is not surprising that ECs are tuned by this tuning protein. However, the
18 modifiability of plaque biology in the EC-specific CTGF knockout, as well as the
19 CTGF antibody treatment, suggests that manipulation of this pathway is feasible for
20 clinical translation. How this occurs is not yet clear but subject to future investigation.
21 It is important to note limitations of this work that warrant future work. Here we
22 present an animal model of stiffness + d-flow that mimics human PAD. Certainly, no

1 animal model perfectly mimics the human condition. Arterial stiffness and other
2 mechanical parameters differ between mouse and human arteries. However, relative
3 changes between mice and human arteries do appear to be conserved.⁴⁷ Here, we
4 have demonstrated that the Fbln5 KO has stiff arteries that mimic the stiffness of PAD
5 arteries after 4 weeks of d-flow, have baseline endothelial dysfunction, and develop
6 an aggressive atherosclerotic plaque phenotype under atherogenic conditions.
7 Mechanically, matrix components, collagen and elastin, drive arterial mechanics.
8 Since the Fbln5 KO mimics vascular aging due to a defect in elastic fiber assembling,
9 we were not surprised that unmanipulated KO RCAs mimicked the mechanics of
10 aged arteries. We were excited that the addition of d-flow further stiffened these
11 arteries, and that this stiffening mimicked the ratios seen in PAD arteries compared
12 to their controls. Further, it was surprising to see the similar stair-step upregulation of
13 CTGF in KO compared to WT and d-flow compared to s-flow, and in young/aged and
14 d-flow compared to s-flow arteries, supporting the shared pathways of arterial aging
15 and PAD. The validation of this in d-flow areas of vascular tissue from patients further
16 supports the likely importance of these relationships in PAD. Still, there are additional
17 downstream pathways in our data set that are likely important to the EC contribution
18 to arterial stiffening and flow-mediated atherosclerotic plaque under PAD conditions.
19 It is our hope that others will integrate stiff + d-flow into their discovery science to
20 build a better understanding of therapeutic opportunities in the PAD space.
21 Matricellular proteins, like CTGF, are of particular interest under PAD conditions, as
22 they may be targeted to dampen signaling pathways important to flow-mediated

1 stiffening and progressive atherosclerotic plaque progression in a favorable manner.
2 Also, relatively little is known about the sex-based differences in EC plasticity,
3 particularly if there is a sex-based difference that is cued by stiffness and d-flow. This
4 work has not exhaustively proven that CTGF is not important to d-flow mediated ASD
5 in females. This is an area of active discovery in our laboratory. Interestingly, the lack
6 of difference in atherosclerotic plaque in ECKO^{CTGF} and ECWT^{CTGF} was not due to
7 differences in absolute stiffness under biaxial arterial testing. It still may relate to the
8 relative response of EC to stiffness + d-flow, particularly as it relates to EC plasticity
9 pathways, but this remains to be proven.

10 In summary, this work characterized a novel model of PAD mechanics, identified
11 unique molecular signatures related to PAD mechanics that involve precocious EC
12 plasticity, identified an important role for CTGF in d-flow mediated arterial remodeling
13 and in PAD vasculature, and identified that CTGF inhibition therapies may play a
14 favorable role in limiting the impact of PAD on vascular health and flow-mediated
15 atherosclerotic plaque behavior.

16

17 **References**

- 18 1. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. *Circ Res.*
19 2015;116:1509-1526. doi: 10.1161/CIRCRESAHA.116.303849
- 20 2. Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, McDermott MM, Misra
21 S, Ujueta F, American Heart Association Council on E, et al. Lower Extremity Peripheral
22 Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A

- 1 Scientific Statement From the American Heart Association. *Circulation*. 2021;144:e171-e191.
- 2 doi: 10.1161/CIR.0000000000001005
- 3 3. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE,
- 4 Sampson UK, Williams LJ, Mensah GA, et al. Comparison of global estimates of prevalence
- 5 and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and
- 6 analysis. *Lancet*. 2013;382:1329-1340. doi: 10.1016/s0140-6736(13)61249-0
- 7 4. Criqui MH, Ninomiya JK, Wingard DL, Ji M, Fronek A. Progression of peripheral arterial
- 8 disease predicts cardiovascular disease morbidity and mortality. *J Am Coll Cardiol*.
- 9 2008;52:1736-1742. doi: S0735-1097(08)02959-8 [pii] 10.1016/j.jacc.2008.07.060
- 10 5. Chung J, Timaran DA, Modrall JG, Ahn C, Timaran CH, Kirkwood ML, Baig MS, Valentine RJ.
- 11 Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia. *J*
- 12 *Vasc Surg*. 2013;58:972-980. doi: 10.1016/j.jvs.2013.03.050
- 13 6. Zamani MC, Y-H; Charbonier F; Gupta, VK; Mayer, AT; Trevino, AE; Quertermous, T;
- 14 Chaudhuri, O; Cahan, P; Huang, NF. Single-Cell Transcriptomic Census of Endothelial
- 15 Changes Induced by Matrix Stiffness and the Association with Atherosclerosis. *Advanced*
- 16 *Functional Materials*. 2022. doi: 10.1002/adfm.202203069
- 17 7. Kim CW, Pokutta-Paskaleva A, Kumar S, Timmins LH, Morris AD, Kang DW, Dalal S, Chadid
- 18 T, Kuo KM, Raykin J, et al. Disturbed Flow Promotes Arterial Stiffening Through
- 19 Thrombospondin-1. *Circulation*. 2017;136:1217-1232. doi:
- 20 10.1161/circulationaha.116.026361
- 21 8. Andueza A, Kumar S, Kim J, Kang DW, Mumme HL, Perez JI, Villa-Roel N, Jo H. Endothelial
- 22 Reprogramming by Disturbed Flow Revealed by Single-Cell RNA and Chromatin Accessibility

- 1 Study. *Cell Rep.* 2020;33:108491. doi: 10.1016/j.celrep.2020.108491
- 2 9. Abbas AE, Zacharias SK, Goldstein JA, Hanson ID, Safian RD. Invasive characterization of
3 atherosclerotic plaque in patients with peripheral arterial disease using near-infrared
4 spectroscopy intravascular ultrasound. *Catheter Cardiovasc Interv.* 2017;90:461-470. doi:
5 10.1002/ccd.27023
- 6 10. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT, Bax JJ, van
7 Sambeek MR, Poldermans D. Long-term prognosis of patients with peripheral arterial disease:
8 a comparison in patients with coronary artery disease. *J Am Coll Cardiol.* 2008;51:1588-1596.
9 doi: 10.1016/j.jacc.2007.11.077
- 10 11. Hemerich D, van der Laan SW, Tragante V, den Ruijter HM, de Borst GJ, Pasterkamp G, de
11 Bakker PI, Asselbergs FW. Impact of carotid atherosclerosis loci on cardiovascular events.
12 *Atherosclerosis.* 2015;243:466-468. doi: 10.1016/j.atherosclerosis.2015.10.017
- 13 12. Piller LB, Simpson LM, Baraniuk S, Habib GB, Rahman M, Basile JN, Dart RA, Ellsworth AJ,
14 Fendley H, Probstfield JL, et al. Characteristics and long-term follow-up of participants with
15 peripheral arterial disease during ALLHAT. *Journal of general internal medicine.*
16 2014;29:1475-1483. doi: 10.1007/s11606-014-2947-1
- 17 13. Yin D, Matsumura M, Rundback J, Yoho JA, Witzenbichler B, Stone GW, Mintz GS, Maehara
18 A. Comparison of plaque morphology between peripheral and coronary artery disease (from
19 the CLARITY and ADAPT-DES IVUS substudies). *Coron Artery Dis.* 2017;28:369-375. doi:
20 10.1097/MCA.0000000000000469
- 21 14. Aronow HD, Beckman JA. Parsing Atherosclerosis: The Unnatural History of Peripheral Artery
22 Disease. *Circulation.* 2016;134:438-440. doi: 10.1161/CIRCULATIONAHA.116.022971

- 1 15. Chen DC, Singh GD, Armstrong EJ, Waldo SW, Laird JR, Amsterdam EA. Long-Term
2 Comparative Outcomes of Patients With Peripheral Artery Disease With and Without
3 Concomitant Coronary Artery Disease. *Am J Cardiol.* 2017;119:1146-1152. doi:
4 10.1016/j.amjcard.2016.12.023
- 5 16. Wang R, Raykin J, Li H, Gleason RL, Jr., Brewster LP. Differential mechanical response and
6 microstructural organization between non-human primate femoral and carotid arteries.
7 *Biomech Model Mechanobiol.* 2014. doi: 10.1007/s10237-014-0553-0
- 8 17. Labropoulos N, Leon LR, Jr., Brewster LP, Pryor L, Tiongson J, Kang SS, Mansour MA,
9 Kalman P. Are your arteries older than your age? *Eur J Vasc Endovasc Surg.*
10 2005;30:588-596. doi: S1078-5884(05)00382-5 [pii] 10.1016/j.ejvs.2005.06.011
- 11 18. Xu Y, Kovacic JC. Endothelial to Mesenchymal Transition in Health and Disease. *Annu Rev*
12 *Physiol.* 2022. doi: 10.1146/annurev-physiol-032222-080806
- 13 19. Coutinho T, Rooke TW, Kullo IJ. Arterial dysfunction and functional performance in patients
14 with peripheral artery disease: a review. *Vasc Med.* 2011;16:203-211. doi:
15 10.1177/1358863X11400935
- 16 20. Anttila E, Balzani D, Desyatova A, Deegan P, MacTaggart J, Kamenskiy A. Mechanical
17 damage characterization in human femoropopliteal arteries of different ages. *Acta Biomater.*
18 2019;90:225-240. doi: 10.1016/j.actbio.2019.03.053
- 19 21. Kamenskiy A, Poulson W, Sim S, Reilly A, Luo J, MacTaggart J. Prevalence of Calcification in
20 Human Femoropopliteal Arteries and its Association with Demographics, Risk Factors, and
21 Arterial Stiffness. *Arterioscler Thromb Vasc Biol.* 2018;38:e48-e57. doi:
22 10.1161/ATVBAHA.117.310490

- 1 22. Poulson W, Kamenskiy A, Seas A, Deegan P, Lomneth C, MacTaggart J. Limb
2 flexion-induced axial compression and bending in human femoropopliteal artery segments. *J*
3 *Vasc Surg*. 2018;67:607-613. doi: 10.1016/j.jvs.2017.01.071
- 4 23. Murtada SI, Ferruzzi J, Yanagisawa H, Humphrey JD. Reduced Biaxial Contractility in the
5 Descending Thoracic Aorta of Fibulin-5 Deficient Mice. *J Biomech Eng*. 2016;138:051008. doi:
6 10.1115/1.4032938
- 7 24. Yanagisawa H, Davis EC. Unraveling the mechanism of elastic fiber assembly: The roles of
8 short fibulins. *Int J Biochem Cell Biol*. 2010;42:1084-1093. doi: 10.1016/j.biocel.2010.03.009
- 9 25. Yanagisawa H, Schluterman MK, Brekken RA. Fibulin-5, an integrin-binding matricellular
10 protein: its function in development and disease. *J Cell Commun Signal*. 2009;3:337-347. doi:
11 10.1007/s12079-009-0065-3
- 12 26. Yanagisawa H, Davis EC, Starcher BC, Ouchi T, Yanagisawa M, Richardson JA, Olson EN.
13 Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. *Nature*.
14 2002;415:168-171. doi: 10.1038/415168a
- 15 27. Wan W, Yanagisawa H, Gleason RL, Jr. Biomechanical and microstructural properties of
16 common carotid arteries from fibulin-5 null mice. *Ann Biomed Eng*. 2010;38:3605-3617. doi:
17 10.1007/s10439-010-0114-3
- 18 28. Nam D, Ni CW, Rezvan A, Suo J, Budzyn K, Llanos A, Harrison D, Giddens D, Jo H. Partial
19 carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial
20 dysfunction and atherosclerosis. *Am J Physiol Heart Circ Physiol*. 2009;297:H1535-1543. doi:
21 10.1152/ajpheart.00510.2009
- 22 29. Kumar S, Kang DW, Rezvan A, Jo H. Accelerated atherosclerosis development in C57Bl6

- 1 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation. *Lab Invest.*
2 2017;97:935-945. doi: 10.1038/labinvest.2017.47
- 3 30. Glagov S, Bassiouny HS, Sakaguchi Y, Goudet CA, Vito RP. Mechanical determinants of
4 plaque modeling, remodeling and disruption. *Atherosclerosis.* 1997;131 Suppl:S13-14. doi:
5 10.1016/s0021-9150(97)06117-0
- 6 31. Gimbel AT, Koziarek S, Theodorou K, Schulz JF, Stanicek L, Kremer V, Ali T, Gunther S,
7 Kumar S, Jo H, et al. Aging-regulated TUG1 is dispensable for endothelial cell function. *PLoS*
8 *One.* 2022;17:e0265160. doi: 10.1371/journal.pone.0265160
- 9 32. Aguilar VM, Paul A, Lazarko D, Levitan I. Paradigms of endothelial stiffening in cardiovascular
10 disease and vascular aging. *Front Physiol.* 2022;13:1081119. doi:
11 10.3389/fphys.2022.1081119
- 12 33. Mendes-Pinto D, Rodrigues-Machado MDG, Avelar GL, Navarro TP, Dardik A. Arterial
13 stiffness predicts amputation and death in patients with chronic limb-threatening ischemia. *J*
14 *Vasc Surg.* 2021;74:2014-2022 e2014. doi: 10.1016/j.jvs.2021.05.052
- 15 34. Evrard SM, Lecce L, Michelis KC, Nomura-Kitabayashi A, Pandey G, Purushothaman KR,
16 d'Escamard V, Li JR, Hadri L, Fujitani K, et al. Endothelial to mesenchymal transition is
17 common in atherosclerotic lesions and is associated with plaque instability. *Nat Commun.*
18 2016;7:11853. doi: 10.1038/ncomms11853
- 19 35. Huang X, Yang N, Fiore VF, Barker TH, Sun Y, Morris SW, Ding Q, Thannickal VJ, Zhou Y.
20 Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic
21 mechanotransduction. *Am J Respir Cell Mol Biol.* 2012;47:340-348. doi:
22 10.1165/rcmb.2012-0050OC

- 1 36. Wei SC, Fattet L, Tsai JH, Guo Y, Pai VH, Majeski HE, Chen AC, Sah RL, Taylor SS, Engler
2 AJ, et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis
3 through a TWIST1-G3BP2 mechanotransduction pathway. *Nat Cell Biol.* 2015;17:678-688.
4 doi: 10.1038/ncb3157
- 5 37. Tang Y, Feinberg T, Keller ET, Li XY, Weiss SJ. Snail/Slug binding interactions with YAP/TAZ
6 control skeletal stem cell self-renewal and differentiation. *Nat Cell Biol.* 2016;18:917-929. doi:
7 10.1038/ncb3394
- 8 38. Wang KC, Yeh YT, Nguyen P, Limqueco E, Lopez J, Thorossian S, Guan KL, Li YJ, Chien S.
9 Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis.
10 *Proc Natl Acad Sci U S A.* 2016;113:11525-11530. doi: 10.1073/pnas.1613121113
- 11 39. Leask A. Et tu, CCN1. *J Cell Commun Signal.* 2020;14:355-356. doi:
12 10.1007/s12079-020-00573-4
- 13 40. Ponticos M. Connective tissue growth factor (CCN2) in blood vessels. *Vascul Pharmacol.*
14 2013;58:189-193. doi: 10.1016/j.vph.2013.01.004
- 15 41. Cicha I, Yilmaz A, Klein M, Raithel D, Brigstock DR, Daniel WG, Goppelt-Struebe M, Garlich
16 CD. Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques
17 and induces mononuclear cell chemotaxis in vitro. *Arterioscler Thromb Vasc Biol.*
18 2005;25:1008-1013. doi: 10.1161/01.ATV.0000162173.27682.7b
- 19 42. Pabon M, Cheng S, Altin SE, Sethi SS, Nelson MD, Moreau KL, Hamburg N, Hess CN. Sex
20 Differences in Peripheral Artery Disease. *Circ Res.* 2022;130:496-511. doi:
21 10.1161/CIRCRESAHA.121.320702
- 22 43. DuPont JJ, Kim SK, Kenney RM, Jaffe IZ. Sex differences in the time course and mechanisms

- 1 of vascular and cardiac aging in mice: role of the smooth muscle cell mineralocorticoid
2 receptor. *Am J Physiol Heart Circ Physiol.* 2021;320:H169-H180. doi:
3 10.1152/ajpheart.00262.2020
- 4 44. Mitchell GF. Arterial Stiffness and Wave Reflection: Biomarkers of Cardiovascular Risk. *Artery*
5 *Res.* 2009;3:56-64. doi: 10.1016/j.artres.2009.02.002
- 6 45. Regnault V, Thomas F, Safar ME, Osborne-Pellegrin M, Khalil RA, Pannier B, Lacolley P. Sex
7 difference in cardiovascular risk: role of pulse pressure amplification. *J Am Coll Cardiol.*
8 2012;59:1771-1777. doi: 10.1016/j.jacc.2012.01.044
- 9 46. Brown AJ, Teng Z, Evans PC, Gillard JH, Samady H, Bennett MR. Role of biomechanical
10 forces in the natural history of coronary atherosclerosis. *Nat Rev Cardiol.* 2016;13:210-220.
11 doi: 10.1038/nrcardio.2015.203
- 12 47. Suo J, Ferrara DE, Sorescu D, Guldberg RE, Taylor WR, Giddens DP. Hemodynamic shear
13 stresses in mouse aortas: implications for atherogenesis. *Arterioscler Thromb Vasc Biol.*
14 2007;27:346-351. doi: 10.1161/01.ATV.0000253492.45717.46
- 15
















Figure 1: Fibulin-5 Knockout (KO) Mimics the Hemodynamics and EC Dysfunction of PAD



VE-cadherin/ α-SMA/ DAPI

Figure 2: EC Plasticity in KO Carotid Arteries Under D-flow.






Figure 3: PAD Conditions (Stiff + D-flow) Induce Vulnerable Plaque Phenotype.




Figure 4: CTGF Expression is Flow-mediated and Upregulated in KO and Aged Murine Arteries, and in PAD Arteries.




Figure 5: Endothelial Cell CTGF Knockout (ECKO^{CTGF}) Decreases Plaque Area and Macrophage Infiltration in Male Mice Carotid Arteries Under D-Flow.




Figure 6: CTGF Antibody (FG3149) Decreases Lipid Content and Necrotic Area in Male Mice Carotid Arteries Under D-Flow.




Figure 7: CTGF Inhibition Improves Arterial Compliance During Disturbed Flow Mediated Arterial Remodeling.

Figure 1: Fibulin-5 Knockout (KO) Mimics the Hemodynamics and EC Dysfunction of PAD.

A. In order to compare relative biomechanical changes between wildtype (black line) and KO animal arteries (dotted line), an elastic modulus ratio was calculated from the left common carotid arteries (LCA exposed to d-flow) and the right common carotid arteries (RCA exposed to s-flow) over physiologic mean arterial pressures. We then calculated an elastic modulus ratio for PAD arteries compared to healthy arteries. Mean average ratio and standard deviation is superimposed as a triangle and blue line to the right of the curves. The KO artery ratio over physiologic mean pressures is greater than that of WT arteries and very similar to that of PAD arteries (blue triangle). **B.** To compare basal stiffness of KO carotid arteries to that of aged animals (80 weeks; ~18 months), we compared s-flow KO RCA to that of aged mice. While most of the pressure ranges had similar stiffness, the KO RCA was stiffer than aged arteries from 60-80 mmHg. (KO n= 6-7; 4 males/3 females) **C/D.** To quantify flow-mediated stiffening in KO arteries, pressure-diameter and compliance curves were generated from biaxial testing to demonstrate that the d-flow KO carotid arteries were circumferentially stiffer than the contralateral s-flow RCAs. **E.** To test longitudinal stiffening, aged arteries were compared to KO under s-flow and d-flow. Here there was sequential stiffening with d-flow KO least compliant. Symbols indicate statistical significance. **F.** Residual stress is a measurement of pathologic forces in the arterial wall. Opening angles in both KO RCA and LCA were exuberant but similar. **G/H.** To compare baseline endothelial cell dysfunction, endothelial cell dependent (G, N=6) and independent (H, N=6) relaxation was quantified via arterial ring testing. WT: 2 male, 4 female; KO: 3 male, 3 female. (**B-D:** Unpaired multiple t-tests with Holm-Sidak method; **E:** One-way ANOVA with Tukey's post hoc test; **G/H:** Two-Way ANOVA with Tukey's post hoc test (*p<0.05 compared to WT).

Figure 2: EC Plasticity in KO Carotid Arteries Under D-flow.

A/B. Representative duplex ultrasonography images of KO RCA and LCA two weeks after PCL. **C.** LCAs with d-flow manifest low and oscillatory WSS throughout the cardiac cycle (blue curve) compared to RCA (orange curve). **D.** 24 hours after PCL, intimal RNA expression of PECAM-1 was reduced in KO LCA endothelium compared to RCA. No significant change was observed in α -SMA and CD11b expression (**D:** Mean \pm SD; unpaired t-test with significance set at P<0.05; n=3). **E-H.** En face immunofluorescence staining of the intima demonstrates robust α -SMA expression in the endothelium of KO LCAs (**H**) after 72 hours under d-flow. Scale bar: 50 μ m. **I/J.** Cluster pathway analysis identified differentially expressed genes (DEGs) in WT (**I**) and KO (**J**) arteries. Cell cycle and changes in the actin cytoskeleton predominated in the WT animals, while EndMT and TGF-beta/Wnt cytoskeletal remodeling was more prominent in KO consistent with cell stiffening and EC plasticity

pathways.

Figure 3: PAD Conditions (Stiff + D-flow) Induce Vulnerable Plaque Phenotype.

A-E. Representative images of Oil Red O (ORO), H&E, Masson's trichrome, elastin autofluorescence and IHC staining of macrophages (CD68) of the LCA from WT and KO animals. **F.** KO LCAs showed significant larger atherosclerotic plaque burden. **G.** Lipid deposition within the plaques is higher in KO mice. **H/I.** Plaques in KO mice had increased necrotic area and greater macrophage infiltration. **J/K.** KO arteries had thinner medial layers than WT, but no difference in intima/media ratio. **L/M.** KO LCAs had increased inner and outer diameters of their lumen and arterial walls than WT. **N.** KO LCA also had increased elastin breaks compared to WT LCAs. **O/P.** In contrast, WT LCAs developed more collagen content in the plaque; collagen content in the rest of the arterial wall was similar. WT n=12 (7 males/ 5 females) and KO n=10 (5 males/ 5 females) in ORO quantification; WT n=8 (4 males/4 females) and KO n=7 (4 males/3 females) in the rest quantifications; male and female mice are represented with blue and pink symbols, respectively; data expressed as mean ± SD; unpaired t-test with significance set at P<0.05. Scale: 50 µm.

Figure 4: CTGF Expression is Flow-mediated and Upregulated in Stiffened KO and Aged Murine Arteries and Under d-flow in PAD Arteries and Carotid Endarterectomy Specimens.

A. D-flow increases CTGF expression in LCAs. WT LCA and pre-stiffened, KO RCAs have similar CTGF expression levels, and CTGF is further increased in KO LCA compared to KO RCA. **B.** Similarly, CTGF expression is increased under d-flow in the LCA of young mice over that of s-flow RCAs, and to a similar degree as s-flow RCAs in old mice (80 weeks old). LCAs in older mice under d-flow is significantly increased over that of young d-flow and aged s-flow. **C/D.** The intima and rest of artery of both PAD arteries and CEA plaques under d-flow have increased CTGF deposition over that of aged healthy control arteries, respectively. **E-G.** Representative images of IHC staining of CTGF in healthy aged peripheral arteries, PAD arteries and carotid artery plaque. n=6 for healthy group; n=7 for PAD group; n=16 for CEA; mean ± SD; one-way ANOVA with Tukey's post hoc test. Scale: 50 µm.

Figure 5: Endothelial Cell CTGF Knockout (ECKO^{CTGF}) Decreases Plaque Area and Macrophage Infiltration in Male Mice Carotid Arteries Under D-Flow.

A-E. Representative images of Oil Red O (ORO), H&E, Masson's trichrome,

elastin autofluorescence and IHC staining of macrophages (CD68) of the LCAs from EC knockout of CTGF (ECKO^{CTGF}) and WT (ECWT^{CTGF}) animals. **F.** ECKO^{CTGF} mice have less atherosclerotic plaque area than control. **G/H.** Lipid deposition and necrotic area are similar between groups. **I.** ECKO^{CTGF} mice have less macrophage infiltration. **J/K.** ECWT^{CTGF} and ECKO^{CTGF} mice have similar medial thickness and intima/media ratio. **L/M.** The Inner luminal and outer arterial wall diameters of LCAs are similar between groups. **N-P.** There are no differences between groups in elastin breaks or the collagen content of the arterial intima or rest of arterial wall. ECWT^{CTGF} n=5; ECKO^{CTGF} n=5. Data expressed as mean ± SD; unpaired t-test with significance set at P<0.05. Scale: 50 µm.

Figure 6: CTGF Antibody (FG-3149) Decreases Lipid Content and Necrotic Area in Male Mice Carotid Arteries Under D-Flow.

A-E. Representative images of Oil Red O (ORO), H&E, Masson's trichrome, elastin autofluorescence and IHC staining of macrophages (CD68) of the LCAs. **F.** FG-3149 treatment did not decrease atherosclerotic plaque area change. **G/H.** FG-3149 treatment decreased lipid accumulation and necrotic area. **I.** There was a trend towards decreased macrophage infiltration in the FG3149 treatment group. **J/K.** There were no differences in medial thickness or the intima/media ratio. **L/M.** There were no differences in the Inner luminal or outer arterial wall diameters between groups. **N-P.** There were no differences in elastin breaks or the collagen content within the intima or rest of arterial wall. IgG Sham antibody group n=6; FG-3149 group n=6; mean ± SD; unpaired t-test with significance set at P<0.05. Scale: 50 µm.

Figure 7: CTGF Inhibition Improves Arterial Compliance During Disturbed Flow Mediated Arterial Remodeling.

A. Pressure-compliance curve of wild type (ECWT^{CTGF}) animals demonstrate decreased arterial compliance in LCAs under 10-80mmHg range (LCA n=4; RCA n=3; all male). Two-way ANOVA w/ Tukey correction. * p<0.05, [p=0.0006 p=0.0102 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p<0.0001] **B.** Pressure-compliance curves of ECKO^{CTGF} have a narrower range of pressures (10, 30-70 mmHg) that have a significant difference in arterial compliance between the LCA and RCA. (LCA n=3; RCA n=3; all male). Two-way ANOVA w/ Tukey's posthoc *p<0.05 [p=0.028 p=0.0019 p<0.0001 p=0.0010] **C.** LCA from ECWT^{CTGF} trend toward significant axial stiffening as measured by axial stretch in the LCA versus RCA; axial compliance is preserved in ECKO^{CTGF} LCAs. One-way ANOVA w/ Tukey correction, nonsignificant. n=10, n=9, n=7 n=6 (RCA, LCA, KO-RCA, KO-LCA, respectively); p-values in figure. **D.** There were no differences in the opening angles between RCA and LCA in in the wild type (ECWT^{CTGF}: black/grey) or EC CTGF KO (ECKO^{CTGF}: purple and pink). Under atherogenic conditions, the wild type ECWT^{CTGF} animal has significantly

greater residual stresses compared to ECKO^{CTGF} in the d-flow LCA. ECWT^{CTGF} RCA (n=27); ECWT^{CTGF} LCA (n=24); ECKO^{CTGF} RCA (n=15); ECKO^{CTGF} LCA (n=15); ECWT^{CTGF} LCA-plaque (n=20); ECKO^{CTGF} LCA-plaque (n=16). Ordinary one way ANOVA w/ Tukey's correction, ECWT^{CTGF} LCA-plaque ECKO^{CTGF} LCA-plaque *p<0.0001 **E.** Pressure-compliance curves of carotid arteries from wild type (ECWT^{CTGF}) animals treated with sham IgG antibody demonstrate decreased arterial compliance in LCAs under 10-70mmHg range (LCA n=11; RCA n=11; 6 male/5 female). Two-way ANOVA w/ Tukey's correction *p<0.05 [p=0.0283 p=0.0216 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p<0.0001 p=0.0215] **F.** Pressure-compliance curves of carotid arteries from ECWT^{CTGF} treated with CTGF antibody (FG-3149) have a narrower range of pressures (40-80mmHg) that have a significant difference in arterial compliance between the LCA and RCA (LCA n=10; RCA n=10; 6 male, 4 female). Two-way ANOVA w/ Tukey's correction *p<0.05 [p=0.0006 p<0.0001 p<0.0001 p=0.0008 p=0.0477] **G.** There is a significant difference in axial stiffening under d-flow (LCA) in the IgG treated animals. This is attenuated and not significant in the CTGF antibody (FG-3149) treated animals. RCA IgG n=11, LCA IgG n=10, RCA FG3149 n=10, LCA FG3149 n=10). Ordinary one-way ANOVA w/ Tukey's correction. P value in figure.